医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Aegis Spine’s Attempt to Stay Court Order Halting Sale of Their AccelFix-XT Denied, Life Spine Announces

2021年05月07日 AM01:22
このエントリーをはてなブックマークに追加


 

HUNTLEY, Ill.

Life Spine won a second ruling barring Aegis Spine, Inc. from marketing, selling, or distributing devices in its AccelFix-XT product line.

A preliminary injunction preventing Aegis’s marketing and sale of its AccelFix-XT line of expandable medical devices has been in effect since April 5, 2021. Aegis’s attempt to stay the injunction was denied on May 4, 2021.

The United States District Court for the Northern District of Illinois issued the injunction after finding that Aegis and its parent company, L&K Biomed Co., Ltd., used Life Spine’s proprietary PROLIFT® expandable cage to develop the AccelFix-XT. In response to Aegis’ motion to stay the injunction pending its appeal to the Seventh Circuit, the Court reaffirmed its finding that “Life Spine has a high likelihood of success on its [various] claims based on evidence that, among other things, Aegis took calculated steps to help copy or reverse engineer the PROLIFT implant, disclosed Life Spine’s confidential information to third parties, shipped the PROLIFT implant to a third party without Life Spine’s knowledge or permission, and failed to train its employees regarding its contractual confidentiality obligations.”

Given the Court’s wholesale rejection of Aegis’s arguments, the injunction preventing Aegis’s marketing and sale of any items in the AccelFix-XT product line remains in effect.

Life Spine’s CEO Michael Butler said of the ruling: “The Court’s ruling validates our claims and we appreciate the thorough analysis of the issues presented. The ruling protects the propriety technology around our PROLIFT Expandable Implants.”

About Life Spine

Life Spine is an industry-leading medical device company that specializes in providing innovative, Micro Invasive solutions to address a wide range of spinal pathologies. Life Spine is dedicated to improving the quality of life for patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine is pleased to offer its top-performing PROLIFT® expandable spacer system as part of this mission.

For Full Opinion and Order Visit – https://www.docketalarm.com/cases/Illinois_Northern_District_Court/1–19-cv-07092/Life_Spine_Inc._v._Aegis_Spine_Inc/254/

View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005946/en/

CONTACT

Heather Glaser

General Counsel

hglaser@lifespine.com

847-884-6117

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™